Raphael J. Landovitz
Infectious Disease · The Regents of the University of California
Credentials: · · · ·
History
- Until 2001
- Until 1999
Research
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
New England Journal of Medicine · 2021 · First of 66 authors · 759 citations
JAMA · 2016 · 522 citations
JAMA · 2023 · 462 citations
- JR
22 papers
- CH
20 papers
- SE
19 papers
18 papers
17 papers
- AA
15 papers
- SS
14 papers
12 papers
Grants
- 2006–2027
HIV Prevention Trials Network Leadership and Operations Center
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $40M · Family Health International
- 2007–2027
UCLA AIDS Prevention and Treatment Clinical Trials Unit
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $26.5M · University of California Los Angeles
- 1997–2026
Center for HIV Identification, Prevention and Treatment Services
National Institute of Mental Health · P30
Contact PI · $3.3M · University of California Los Angeles
- 2009–2014
Biomedical Prevention for HIV in High-Risk Populations with Comorbidities
National Institute on Drug Abuse · K23
Contact PI · $790K · University of California Los Angeles
Clinical trials
- 2016–2019
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
Principal investigator · Completed · Phase 4
University of California, Los Angeles
- 2015–2031
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Principal investigator · Active not recruiting
Calimmune, Inc.
- 2013–2016
Principal investigator · Completed · Phase 4
University of California, Los Angeles
- 2010–2013
Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
Principal investigator · Completed · Phase 2
Friends Research Institute, Inc.